XORTX Therapeutics Inc. – NASDAQ:XRTX
XORTX Therapeutics stock price today
XORTX Therapeutics stock price monthly change
XORTX Therapeutics stock price quarterly change
XORTX Therapeutics stock price yearly change
XORTX Therapeutics key metrics
Market Cap | 3.86M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.38 |
Revenue | N/A |
EBITDA | -5.13M |
Income | -3.33M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeXORTX Therapeutics stock price history
XORTX Therapeutics stock forecast
XORTX Therapeutics financial statements
| Jun 2023 | 0 | -1.69M | |
|---|---|---|---|
| Sep 2023 | 0 | -1.33M | |
| Dec 2023 | 0 | 2.69M | |
| Mar 2024 | 0 | -3.00M |
| Mar 2024 | 0 | -3.00M | |
|---|---|---|---|
| Sep 2025 | 0 | -745.80K | |
| Dec 2025 | 0 | -586.4K | |
| Dec 2025 | 0 | -713.37K |
Analysts Price target
Financials & Ratios estimates
| 2023-03-31 | -0.27 | -0.15 |
|---|---|---|
| 2023-08-14 | -0.15 | -0.09 |
| Jun 2023 | 7801168 | 403.26K | 5.17% |
|---|---|---|---|
| Sep 2023 | 6640147 | 553.75K | 8.34% |
| Dec 2023 | 5439988 | 821.71K | 15.11% |
| Mar 2024 | 6044360 | 3.55M | 58.83% |
| Jun 2023 | -1.73M | -9.53K | -8.76K |
|---|---|---|---|
| Sep 2023 | -1.07M | -7.29K | -16.67K |
| Dec 2023 | -1.33M | -10.05K | -318.08K |
| Mar 2024 | -1.29M | -2.61K | 1.69M |
XORTX Therapeutics alternative data
| Aug 2023 | 3 |
|---|---|
| Sep 2023 | 3 |
| Oct 2023 | 3 |
| Nov 2023 | 3 |
| Dec 2023 | 3 |
| Jan 2024 | 3 |
| Feb 2024 | 3 |
| Mar 2024 | 3 |
| Apr 2024 | 3 |
| May 2024 | 3 |
| Jun 2024 | 2 |
| Jul 2024 | 2 |
XORTX Therapeutics other data
-
What's the price of XORTX Therapeutics stock today?
One share of XORTX Therapeutics stock can currently be purchased for approximately $0.77.
-
When is XORTX Therapeutics's next earnings date?
Unfortunately, XORTX Therapeutics's (XRTX) next earnings date is currently unknown.
-
Does XORTX Therapeutics pay dividends?
No, XORTX Therapeutics does not pay dividends.
-
How much money does XORTX Therapeutics make?
XORTX Therapeutics has a market capitalization of 3.86M. XORTX Therapeutics made a loss 2.15M US dollars in net income (profit) last year or -$0.09 on an earnings per share basis.
-
What is XORTX Therapeutics's stock symbol?
XORTX Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "XRTX".
-
What is XORTX Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of XORTX Therapeutics?
Shares of XORTX Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does XORTX Therapeutics have?
As Jul 2024, XORTX Therapeutics employs 2 workers, which is 33% less then previous quarter.
-
When XORTX Therapeutics went public?
XORTX Therapeutics Inc. is publicly traded company for more then 3 years since IPO on 23 Sep 2021.
-
What is XORTX Therapeutics's official website?
The official website for XORTX Therapeutics is xortx.com.
-
Where are XORTX Therapeutics's headquarters?
XORTX Therapeutics is headquartered at 421 – 7th Avenue SW, Vancouver, BC.
-
How can i contact XORTX Therapeutics?
XORTX Therapeutics's mailing address is 421 – 7th Avenue SW, Vancouver, BC.
XORTX Therapeutics company profile:
XORTX Therapeutics Inc.
xortx.comNASDAQ
2
Biotechnology
Healthcare
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Vancouver, BC T2P 4K9
CIK: 0001729214
ISIN: CA98420Q3061
CUSIP: 98420Q207
